Research Article| Volume 48, ISSUE 6, P1323-1329, June 2013

Synergistic effects of HB-EGF and mesenchymal stem cells in a murine model of intestinal ischemia/reperfusion injury



      We have previously demonstrated that heparin-binding EGF-like growth factor (HB-EGF) administration protects the intestines from ischemia/reperfusion (I/R) injury in vivo. We have also shown that HB-EGF promotes mesenchymal stem cell (MSC) proliferation and migration in vitro. The goals of the current study were to examine the effects of HB-EGF and both bone marrow (BM)- and amniotic fluid (AF)-derived MSC on intestinal I/R injury in vivo.

      Materials and Methods

      MSC were isolated from pan-EGFP mice, expanded, and purified. Pluripotency was confirmed by induced differentiation. Mice were subjected to terminal ileum I/R and received either: (1) no therapy; (2) HB-EGF; (3) BM-MSC; (4) HB-EGF + BM-MSC; (5) AF-MSC; or (6) HB-EGF + AF-MSC. MSC engraftment, histologic injury, and intestinal permeability were quantified.


      There was increased MSC engraftment into injured compared to uninjured intestine for all experimental groups, with significantly increased engraftment for AF-MSC + HB-EGF compared to AF-MSC alone. Administration of HB-EGF and MSC improved intestinal histology and intestinal permeability after I/R injury. The greatest improvement was with combined administration of HB-EGF + AF-MSC.


      Both HB-EGF alone and MSC alone can protect the intestines from I/R injury, with synergistic efficacy occurring when HB-EGF and AF-MSC are administered together.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pediatric Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pittenger M.F.
        • Mackay A.M.
        • Beck S.C.
        • et al.
        Multilineage potential of adult human mesenchymal stem cells.
        Science. 1999; 284: 143-147
        • Kawada H.
        • Fujita J.
        • Kinjo K.
        • et al.
        Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction.
        Blood. 2004; 104: 3581-3587
        • Koda M.
        • Okada S.
        • Nakayama T.
        • et al.
        Hematopoietic stem cell and marrow stromal cell for spinal cord injury in mice.
        Neuroreport. 2005; 16: 1763-1767
        • Togel F.
        • Hu Z.
        • Weiss K.
        • et al.
        Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms.
        Am J Physiol Renal Physiol. 2005; 289: F31-F42
        • Zhang J.
        • Gong J.F.
        • Zhang W.
        • et al.
        Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice.
        J Biomed Sci. 2008; 15: 585-594
        • Wei L.
        • Fraser J.L.
        • Lu Z.Y.
        • et al.
        Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhance angiogenesis and neurogenesis after cerebral ischemia in rats.
        Neurobiol Dis. 2012; 46: 635-645
        • Yan Q.
        • Ruan J.W.
        • Ding Y.
        • et al.
        Electro-acupuncture promotes differentiation of mesenchymal stem cells, regeneration of nerve fibers and partial functional recovery after spinal cord injury.
        Exp Toxicol Pathol. 2011; 63: 151-156
        • Wong C.Y.
        • Cheong S.K.
        • Mok P.L.
        • et al.
        Differentiation of human mesenchymal stem cells into mesangial cells in post-glomerular injury murine model.
        Pathology. 2008; 40: 52-57
        • Zarjou A.
        • Kim J.
        • Traylor A.M.
        • et al.
        Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury requiresheme oxygenase-1.
        Am J Physiol Renal Physiol. 2011; 300: F254-F262
        • Weil B.R.
        • Markel T.A.
        • Herrmann J.L.
        • et al.
        Mesenchymal stem cells enhance the viability and proliferation of human fetal intestinal epithelial cells following hypoxic injury via paracrine mechanisms.
        Surgery. 2009; 146: 190-197
        • Baksh D.
        • Song L.
        • Tuan R.S.
        Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy.
        J Cell Mol Med. 2004; 8: 301-316
        • Phinney D.G.
        • Kopen G.
        • Isaacson R.L.
        • et al.
        Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, differentiation.
        J Cell Biochem. 1999; 72: 570-585
        • Baghaban E.M.
        • Jahangir S.
        • Aghdami N.
        Mesenchymal stem cells from murine amniotic fluid as a model for preclinical investigation.
        Arch Iran Med. 2011; 14: 96-103
        • Delo D.M.
        • De Coppi P.
        • Bartsch Jr., G.
        • et al.
        Amniotic fluid and placental stem cells.
        Methods Enzymol. 2006; 419: 426-438
        • DeCoppi P.
        • Bartsch Jr., G.
        • Siddiqui M.M.
        • et al.
        Isolation of amniotic stem cell lines with potential for therapy.
        Nat Biotechnol. 2007; 25: 100-106
        • Peister A.
        • Woodruff M.A.
        • Prince J.J.
        • et al.
        Cell sourcing for bone tissue engineering: amniotic fluid stem cells have a delayed, robust differentiation compared to mesenchymal stem cells.
        Stem Cell Res. 2011; 7: 17-27
        • Besner G.
        • Higashiyama S.
        • Klasbrun M.P.
        Isolation and characterization of a macrophage-derived heparin-binding growth factor.
        Cell Regul. 1990; 1: 811-819
        • Higashiyama S.
        • Abraham J.A.
        • Miller J.
        • et al.
        A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.
        Science. 1991; 251: 936-939
        • Mehta V.B.
        • Besner G.E.
        HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways.
        Growth Factors. 2007; 25: 253-263
        • El-Assal O.N.
        • Paddock H.
        • Marquez A.
        • et al.
        Heparin-binding epidermal growth factor-like growth factor gene disruption is associated with delayed intestinal restitution, impaired angiogenesis, and poor survival after intestinal ischemia in mice.
        J Pediatr Surg. 2008; 43: 1182-1190
        • El-Assal O.N.
        • Radulescu A.
        • Besner G.E.
        Heparin-binding EGF-like growth factor preserves mesenteric microcirculatory blood flow and protects against intestinal injury in rats subjected to hemorrhagic shock and resuscitation.
        Surgery. 2007; 142: 234-242
        • Yu X.
        • Radulescu A.
        • Zorko N.
        • et al.
        Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis.
        Gastroenterology. 2009; 137: 221-230
        • Chen C.L.
        • Yu X.
        • James I.O.
        • et al.
        Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis.
        Lab Invest. 2012; 92: 331-334
        • Watkins D.J.
        • Zhou Y.
        • Chen C.L.
        • et al.
        Heparin-binding EGF-like growth factor protects mesenchymal stem cells.
        J Surg Res. 2012; 177: 359-364
        • Yang J.
        • Watkins D.J.
        • Chen C.L.
        • et al.
        Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis.
        J Am Coll Surg. 2012; 215: 534-545
        • Chiu C.J.
        • McArdle A.H.
        • Brown R.
        • et al.
        Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal.
        Arch Surg. 1970; 101: 478-483
        • Zhang H.
        • Radulescu A.
        • Besner G.E.
        Heparin-binding epidermal growth factor-like growth factor is essential for preservation of gut barrier function after hemorrhagic shock and resuscitation in mice.
        Surgery. 2009; 146: 334-339
        • Davis-Fleischer K.M.
        • Besner G.E.
        Structure and function of heparin-binding EGF-like growth factor (HB-EGF).
        Front Biosci. 1998; 3: d288-d299
        • Tokumara S.
        • Higashiyama S.
        • Endo T.
        • et al.
        Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing.
        J Cell Biol. 2000; 151: 209-220
        • Faull R.J.
        • Stanley J.M.
        • Fraser S.
        • et al.
        HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration.
        Kidney Int. 2001; 59: 614-624
        • Beerli R.R.
        • Hynes N.E.
        Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.
        J Biol Chem. 1996; 271: 6071-6076
        • Elenius K.
        • Paul S.
        • Allison G.
        • et al.
        Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.
        EMBO J. 1997; 16: 1268-1278
        • Nishi E.
        • Prat A.
        • Hospital V.
        • et al.
        N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration.
        EMBO J. 2001; 20: 3342-3350
        • Hospital V.
        • Prat A.
        Nardilysin, a basic residues specific metallopeptidase that mediates cell migration and proliferation.
        Protein Pept Lett. 2004; 11: 501-508
        • Krempera M.
        • Pasini A.
        • Rigo A.
        • et al.
        HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation.
        Blood. 2005; 106: 59-66
        • Ren H.
        • Accili D.
        • Duan C.
        Hypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways.
        Proc Natl Acad Sci U S A. 2010; 107: 5857-5862
        • Xu R.
        • Chen J.
        • Cong X.
        • et al.
        Lovastatin protects mesenchymal stem cells against hypoxi- and serum deprivation-induced apoptosis by activation of pi3k/akt and erk1/2.
        J Cell Biochem. 2008; 103: 256-289
        • Peterson K.M.
        • Aly A.
        • Lerman A.
        • et al.
        Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress.
        Life Sci. 2011; 88: 65-73
        • El-Assal O.N.
        • Besner G.E.
        HB-EGF enhances restitution after intestinal ischemia/reperfusion via PI3K/Akt and MEK/ERK1/2 activation.
        Gastroenterology. 2005; 129: 609-662